tonix
pharmaceuticals
enrolls
first
participant
precision
study
observational
study
facilitate
development
precision
medicine
techniques
vaccines
therapeutics
study
may
lead
biomarkers
tailoring
vaccines
therapeutics
potential
development
human
monoclonal
antibody
therapeutics
results
precision
study
expected
first
half
chatham
globe
newswire
tonix
pharmaceuticals
holding
nasdaq
tnxp
tonix
company
biopharmaceutical
company
today
announced
first
participant
enrolled
observational
precision
study
examine
immune
responses
healthy
volunteers
recovered
asymptomatic
research
part
ongoing
collaboration
columbia
university
tonix
focuses
cell
antibody
responses
virus
causes
research
encompasses
two
projects
study
led
ilya
trakht
associate
research
scientist
columbia
university
vagelos
college
physicians
surgeons
potential
lead
isolation
characterization
therapeutically
relevant
fully
human
monoclonal
antibodies
study
led
sergei
rudchenko
assistant
professor
medical
sciences
columbia
university
vagelos
college
physicians
surgeons
designed
generate
dna
selected
monoclonal
antibodies
identified
ilya
trakht
study
aptamers
potential
identify
biomarkers
protective
immunity
may
lead
accelerated
precision
vaccines
designed
protect
data
precision
study
may
help
guide
research
determine
vaccine
therapeutic
appropriate
individual
basis
said
seth
lederman
president
chief
executive
officer
tonix
pharmaceuticals
work
may
also
guide
selection
appropriate
participants
clinical
trials
vaccines
including
future
human
trials
using
tonix
live
replicating
attenuated
vaccine
candidate
designed
confer
durable
cell
live
modified
horsepox
virus
vaccine
percutaneous
administration
designed
express
spike
protein
virus
causes
elicit
predominant
cell
response
horsepox
vaccinia
closely
related
orthopoxviruses
believed
share
common
ancestor
live
replicating
orthopoxviruses
like
vaccinia
horsepox
engineered
express
foreign
genes
explored
platforms
vaccine
development
possess
large
packaging
capacity
exogenous
dna
inserts
precise
control
exogenous
gene
insert
expression
lack
persistence
genomic
integration
host
strong
immunogenicity
vaccine
ability
rapidly
generate
vector
insert
constructs
readily
manufacturable
scale
ability
provide
direct
antigen
presentation
relative
vaccinia
horsepox
substantially
decreased
virulence
vaccines
designed
single
dose
vaccines
manufactured
conventional
cell
culturing
systems
potential
mass
scale
production
rs
et
al
plos
one
tonix
pharmaceuticals
holding
tonix
biopharmaceutical
company
focused
discovering
licensing
acquiring
developing
small
molecules
biologics
treat
prevent
human
disease
alleviate
suffering
tonix
portfolio
primarily
composed
central
nervous
system
cns
immunology
product
candidates
immunology
portfolio
includes
vaccines
prevent
infectious
diseases
biologics
address
immunosuppression
cancer
autoimmune
diseases
cns
portfolio
includes
small
molecules
biologics
treat
pain
neurologic
psychiatric
addiction
conditions
tonix
lead
vaccine
candidate
live
replicating
vaccine
based
horsepox
viral
vector
platform
protect
primarily
eliciting
cell
response
tonix
expects
data
animal
studies
fourth
quarter
year
live
horsepox
virus
vaccine
percutaneous
administration
development
protect
smallpox
monkeypox
serves
vector
platform
based
tonix
also
developing
live
replicating
vaccine
candidates
prevention
using
bovine
parainfluenza
vector
tonix
lead
cns
candidate
sl
phase
development
management
fibromyalgia
company
expects
topline
data
phase
relief
study
fourth
quarter
tonix
also
currently
enrolling
participants
phase
rally
study
management
fibromyalgia
using
sl
results
expected
second
half
sl
also
development
agitation
alzheimer
disease
alcohol
use
disorder
aud
programs
phase
ready
aad
program
fda
fast
track
designation
tonix
programs
treating
addiction
conditions
also
include
cocaine
esterase
mg
solution
phase
development
treatment
cocaine
intoxication
fda
breakthrough
therapy
designation
cr
tianeptine
oxalate
tablets
another
cns
program
currently
phase
development
daytime
treatment
depression
intranasal
oxytocin
development
treatment
migraine
pain
tonix
preclinical
pipeline
includes
triple
reuptake
inhibitor
new
molecular
entity
developed
treatment
ptsd
monoclonal
antibody
developed
prevent
treat
organ
transplant
rejection
autoimmune
conditions
biologic
developed
treat
gastric
pancreatic
cancers
investigational
new
biologics
approved
indication
sl
cr
investigational
new
drugs
approved
indication
press
release
information
tonix
found
forward
looking
statements
certain
statements
press
release
within
meaning
private
securities
litigation
reform
act
statements
may
identified
use
words
anticipate
believe
forecast
estimate
expect
intend
among
others
statements
based
tonix
current
expectations
actual
results
could
differ
materially
number
factors
could
cause
actual
events
differ
materially
indicated
statements
factors
include
limited
risks
related
failure
obtain
fda
clearances
approvals
noncompliance
fda
regulations
delays
uncertainties
caused
global
pandemic
risks
related
timing
progress
clinical
development
product
candidates
need
additional
financing
uncertainties
patent
protection
litigation
uncertainties
government
third
party
payor
reimbursement
limited
research
development
efforts
dependence
upon
third
parties
substantial
competition
pharmaceutical
development
significant
risks
development
regulatory
approval
commercialization
new
products
tonix
undertake
obligation
update
revise
statement
investors
read
risk
factors
set
forth
annual
report
form
year
ended
december
filed
securities
exchange
commission
sec
march
periodic
reports
filed
sec
date
thereof
tonix
statements
expressly
qualified
risk
factors
cautionary
statements
information
set
forth
herein
speaks
date
thereof
contacts
jessica
morris
corporate
tonix
pharmaceuticals
travis
kruse
media
russo
partners
peter
vozzo
investors
westwicke
